Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares are trading higher by 44.8% to $4.52 during Thursday’s session after the company announced that Eli Lilly And Co (NYSE:LLY) has chosen FHD-909, an oral BRM selective inhibitor, for clinical development.
Foghorn says the drug targets BRG1 mutated non-small cell lung cancer (NSCLC). Selective BRM inhibition is a promising strategy in cancer research, particularly for tumor types like NSCLC with BRG1 mutations, as it can cause tumor cell death while sparing healthy cells. T
This development follows a collaboration between Foghorn and Lilly established in December 2021, aiming ...